Regenicin Stock Performance
| RGIN Stock | USD 0.0001 0.00 0.00% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Regenicin are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Regenicin has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Regenicin is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 1859.00 |
Regenicin |
Regenicin Relative Risk vs. Return Landscape
If you would invest 0.01 in Regenicin on September 3, 2024 and sell it today you would earn a total of 0.00 from holding Regenicin or generate 0.0% return on investment over 90 days. Regenicin is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Regenicin, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Regenicin Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regenicin's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Regenicin, and traders can use it to determine the average amount a Regenicin's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| RGIN |
Based on monthly moving average Regenicin is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regenicin by adding Regenicin to a well-diversified portfolio.
Regenicin Fundamentals Growth
Regenicin Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Regenicin, and Regenicin fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Regenicin Pink Sheet performance.
| Return On Asset | -37.38 | |||
| Current Valuation | 659.26 K | |||
| Shares Outstanding | 153.48 M | |||
| Price To Earning | (9.70) X | |||
| EBITDA | (655.96 K) | |||
| Cash And Equivalents | 2.24 K | |||
| Total Debt | 629.92 K | |||
| Debt To Equity | 0.34 % | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (27.29 K) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 15.49 K | |||
| Retained Earnings | (11.8 M) | |||
| Current Asset | 293 K | |||
| Current Liabilities | 1.83 M | |||
About Regenicin Performance
By examining Regenicin's fundamental ratios, stakeholders can obtain critical insights into Regenicin's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Regenicin is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey. Regenicin operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.Things to note about Regenicin performance evaluation
Checking the ongoing alerts about Regenicin for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Regenicin help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Regenicin generated a negative expected return over the last 90 days | |
| Regenicin has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (639.26 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Regenicin currently holds about 2.24 K in cash with (27.29 K) of positive cash flow from operations. | |
| Roughly 18.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from express.co.uk: The renowned British brand that risks alienating its loyal customers |
- Analyzing Regenicin's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Regenicin's stock is overvalued or undervalued compared to its peers.
- Examining Regenicin's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Regenicin's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Regenicin's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Regenicin's pink sheet. These opinions can provide insight into Regenicin's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Regenicin Pink Sheet
Regenicin financial ratios help investors to determine whether Regenicin Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Regenicin with respect to the benefits of owning Regenicin security.